The care continuum for dementia and other neurodegenerative diseases is often categorized into four key aspects: prevention, detection, treatment, and care. Early detection is paramount to preserving and prolonging brain health, as well as identifying the most suitable treatments. Darmiyan— a CABHI-supported medical technology company with operations out of Toronto, ON, and San Francisco, CA—has developed brain imaging technology that enables early detection of neurodegenerative disorders, such as mild cognitive impairment, Alzheimer’s disease, and dementia.
BrainSee, Darmiyan’s innovative solution, uses an artificial intelligence-powered algorithm to analyze a client’s MRI scans and cognitive test scores to determine their cognitive health and potential disease progression. Results from BrainSee analyses help inform medical professionals of treatment plans to prolong cognitive well-being and postpone, or even prevent, the onset of dementia.
CABHI supported Darmiyan with BrainSee’s clinical validation and helped the company secure trial partners—Baycrest, Hamilton Health Sciences, and University Health Network—to participate in its clinical study.
Having successfully obtained FDA approval, Darmiyan is working towards growth opportunities and additional trial site partners in Canada, and CABHI is helping the company reach these business development milestones.
Darmiyan’s technology is revolutionizing the standard of care for individuals living with mild cognitive impairment, Alzheimer’s disease, and dementia, and CABHI is proud to be accelerating its innovation journey.